Skip to content

How Smoking Causes COPD: Examination of Immune System Changes

How Smoking Causes COPD: Examination of Immune System Changes

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00186719
Enrollment
100
Registered
2005-09-16
Start date
2005-05-31
Completion date
2012-04-30
Last updated
2011-07-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease

Keywords

Chronic Obstructive Pulmonary Disease, Smoking Related Disease, Immune System Changes

Brief summary

A breathing condition known as chronic obstructive pulmonary disease (COPD) caused by cigarette smoking is a major health problem. The way by which smoking leads to lung disease is uncertain. Recent research done in animals provides a description of specific changes (that is a reduction) in these immune cell types as a result of cigarette smoke exposure. The study you have been asked to participate in is a pilot study to see if similar changes occur in humans who smoke. The purpose of this study is to evaluate this new method of testing blood in 3 groups of 10 people: normal non-smoking subjects, subjects who smoke with no history of lung disease and subjects who smoke and have smoking related COPD.

Detailed description

The mechanism by which smoking leads to damage to lung tissue in susceptible hosts, is uncertain. Recently there has been description of specific changes (that is reduction) in the number and activity of certain key immune cell types - dendritic cells- as a result of cigarette smoke exposure. This work was done in animal models and we would like to develop methods that will allow us to examine if similar changes occur in humans who smoke. Reduced number and activity of dendritic cells would be expected to lead to increased incidence of infection - a common problem in patients with COPD. Since dendritic cells come to the lung from the bloodstream, and one can detect them in the circulation, we will look at the dendritic cells that are present in the peripheral blood.

Interventions

None listed

Sponsors

St. Joseph's Healthcare Hamilton
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Age \> 40 years * Healthy Subjects - Non smokers * FEV1/FVC \> 70% predicted * Current Smokers - \> 10 pack year smoking history * FEV1/FVC \> 70% predicted * Current Smokers with COPD - \> 10 pack year smoking history * FEV1/FVC \< 70% predicted * Able to give informed consent

Exclusion criteria

* Healthy Subjects - Reside with smokers * History of lung disease * Current Smokers - History of lung disease

Countries

Canada

Contacts

Primary ContactSusan E Carruthers, MLT
scarruth@stjosham.on.ca905-522-1155
Backup ContactSarah E Goodwin, BA RRT CCRC
sgoodwin@stjosham.on.ca905-522-1155

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026